Biogen Idec/Acorda Strike Licensing Deal For MS Candidate Fampridine-SR
This article was originally published in The Pink Sheet Daily
Biogen gains revenues, Acorda gets a strong partner well-entrenched in the EU MS market.
You may also be interested in...
Acorda’s Ampyra (dalfampridine) is a first-in-class new molecular entity in terms of FDA approval, but the drug substance’s history as a compounded drug raised the concerns necessitating a Risk Evaluation and Mitigation Strategy, FDA’s review documents show.